Structure Therapeutics (NasdaqGM:GPCR) reported positive topline Phase 2 results for its oral GLP-1 receptor agonist ...
A Structure Therapeutics obesity pill helped patients lose an average of nearly 40 pounds in a mid-stage clinical trial, keeping the drug competitive in the growing crowd of oral medications pursuing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results